Later-Line Combination Therapies Used as Treatment in Multiple Myeloma

Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.

Triplets and Quadruplets Now Play Role in Transplant-Ineligible NDMM

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a 79-year-old with newly diagnosed multiple myeloma in the second article of a 2-part series.

Positive Isa-VRd Trials in Transplant-Ineligible Myeloma Show New Approach

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for isatuximab combination treatment in the first article of a 2-part series.

Tailoring Regimens for Different Age Groups With Multiple Myeloma

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series.

Balancing Treatment Efficacy and Adverse Events in Multiple Myeloma

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed the use of carfilzomib-based regimens compared with other options for patients with multiple myeloma, including those refractory to lenalidomide in the first article of a 2-part series.

Assessing The Rationale Behind Triplet Regimens in RRMM

During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed the long-term results of the phase 3 IKEMA study that build the rationale for use of the triplet therapy isatuximab, carfilzomib, and dexamethasone, in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.

Why Triplet Regimens Show Deeper Responses in RRMM

During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed how the use of the isatuximab, carfilzomib, and dexamethasone triplet regimen led to deeper responses in patients with relapsed/refractory multiple myeloma.

Isa-Kd Stands Out Among Subsequent Regimens in Multiple Myeloma

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.

IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series

Sborov Reviews How Isatuximab Fits Into R/R Multiple Myeloma

In the second article of a 2-part series, Douglas Sborov, MD, discusses the toxicities seen with isatuximab and how this therapy can impact patients in rural areas relying on community center treatment.

Isatuximab-Based Triplet Therapy Improves Outcomes in R/R Multiple Myeloma

In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.

Isatuximab Provides Longer Survival in Early Relpase Multiple Myeloma

In the second article of a 2-part series, Joshua Richter, MD, discusses how the isatuximab, carfilzomib, and dexamethasone regimen fits into the landscape of treatment for patients with early relapsed multiple myeloma.

Isatuximab Combo Provides Durable Option in High-Risk Multiple Myeloma

In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.

Discussing the Use of Anti-CD38 Combination Therapy in RRMM

Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.

Reactions to Updated Isatuximab Data in Second-Line Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their views on the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with multiple myeloma.

Next-Line Therapy Choices in R/R Multiple Myeloma After VRd Plus ASCT

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their choice of combination therapy after disease relapse of multiple myeloma.